Gilead

Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases. Read more

50,855 Followers on Owler
50,855 Followers on Owler
50,855 Followers on Owler
50,855 Followers on Owler

Gilead

Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases. Read more

Daniel O’Day's photo - Chairman & CEO of Gilead

Chairman & CEO

Daniel O’Day

CEO Approval Rating

65/100

Founded:

1987

Status:

PublicIndependent CompanyNASDAQGILD

GILEAD TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

AbbVie is perceived as one of Gilead's biggest rivals. AbbVie's headquarters is in North Chicago, Illinois, and was founded in 2013. AbbVie operates in the Pharmaceuticals industry. AbbVie generates 196% of Gilead's revenue.

Merck has been one of Gilead's top competitors. Merck is a Public company that was founded in 1891 in Kenilworth, New Jersey. Merck operates in the Pharmaceuticals industry. Compared to Gilead, Merck has 63,000 more employees.

BMS is Gilead's #3 rival. BMS was founded in New York, New York} in 1858. BMS is in the Pharmaceuticals industry. Compared to Gilead, BMS generates $17.2B more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Novartis a competitor of Gilead?

Gilead Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$25.6B

Gilead's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 26.6B. Over the last four quarters, Gilead's revenue has grown by 24.9%. Specifically, in Q1 2021's revenue was $6.4B; in Q4 2020, it was $7.4B; in Q3 2020, it was $6.6B; in Q2 2020, Gilead's revenue was $5.1B.

Gilead Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
MYR GmbH

Dec 2020

Source »
$1.4B
MYR Pharmaceuticals is a biotechnology company that develops and commercializes therapeutics for the treatment of chronic diseases.
Immunomedics, Inc.

Sep 2020

Source »
$21B
Immunomedics is a biopharmaceutical company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.
Forty Seven, Inc.

Mar 2020

Source »
$4.9B
Forty Seven is a biotechnology company that discovers and develops immuno-oncology therapies for the treatment of cancer.
Cell Design Labs, Inc.

Dec 2017

Source »
$175M
Cell Design Labs focuses on developing CAR-T and T cell receptor therapies for the treatment of cancer.
Kite Pharma, Inc.

Aug 2017

Source »
$11.9B
Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer.

These are all the companies that Gilead has acquired. Gilead has acquired 9 companies and its latest acquisition was MYR GmbH in Dec 2020. MYR Pharmaceuticals is a biotechnology company that develops and commercializes therapeutics for the treatment of chronic diseases.

Gilead Funding History

Since Gilead was founded in 1987, it has participated in 2 rounds of funding. In total Gilead has raised $7.3B. Gilead's last funding round was on Sep 2020 for a total of $7.2B

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Sep 2020
$7.3B
-
IPO
Jan 1992
$86.3M

Since Gilead was founded in 1987, it has participated in 2 rounds of funding. In total Gilead has raised $7.3B. Gilead's last funding round was on Sep 2020 for a total of $7.2B

Gilead Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Vaccitech is an England-based biopharmaceutical company that researches and develops vaccines for the treatment of cancer and infectious diseases.
$168M
Mar 16, 2021
Series B
Apr 29, 2021
Tango Therapeutics is a biotechnology company that develops and commercializes novel therapeutics for the treatment of cancer.
$50M
Aug 17, 2020
Equity
-
Tizona is a biotechnology company that researches, develops and commercializes immunotherapies for the treatment of cancer.
$300M
Jul 20, 2020
Corporate Round
-
Goldfinch Bio is a biotechnology company that develops and commercializes gene therapies for the treatment of kidney diseases.
$100M
Jun 29, 2020
Series B
-
Glympse Bio is a life science company that develops and manufactures noninvasive sensor products for monitoring cancer and infectious diseases.
$46.7M
May 28, 2020
Series B
-

These are all the companies that Gilead has invested in. Gilead has invested 9 companies and its latest investment was MYR GmbH in Dec 2020. MYR Pharmaceuticals is a biotechnology company that develops and commercializes therapeutics for the treatment of chronic diseases.

Gilead News

May 4, 2021STAT News

Gilead sues Russia over a compulsory license issued to a company making remdesivir

Amid worldwide clamoring for Covid-19 vaccines and other therapies, Gilead has filed a lawsuit agains... See more »
April 30, 2021moneycontrol

Exclusive | Gilead Sciences to send 1 lakh Remdesivir vials to India by next week to ease shortage

Consignment is part of 4.5 lakh vials that Gilead Sciences promised to donate to India. The remainder... See more »
April 30, 2021The Pharma Letter

Gilead shares hit as sales figures miss estimates

US biotech major Gilead Sciences was trading 1% lower after an hour's trading on Friday following the... See more »
April 30, 2021PMLiVE

Gilead's Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020... See more »
April 30, 2021Benzinga

Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings

Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slight... See more »
April 30, 2021Contract Pharma

Gilead Revenues up 16% in the Quarter

Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.... See more »
April 29, 2021CNBC

Amazon, Twitter, Gilead Sciences & more

These are the stocks posting the largest moves after the bell on Thursday, April 29.... See more »

Gilead Press Releases

April 23, 2021prFocus

Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer

On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sa... See more »
April 8, 2021StreetInsider

Extension of lock-up period in Gilead-Galapagos collaboration agreement

 Mechelen, Belgium; 08 April 2021; 22.01 CET; Galapagos (Euronext & Nasdaq; GLPG) announced today th... See more »
March 23, 2021GlobalNewswire

Covid-19 Medicine Market worth over USD 28 Million by 2027, Says Brandessence Market Research

Key Companies Covered in the Covid-19 Medicine market: Gilead Sciences, Inc., IPCA, Zydus Cadila, I-M... See more »
March 16, 2021Newswire

The Links Foundation, Incorporated Awarded $350,000 Gilead Sciences Grant to Bolster Its Efforts to Eradicate the HIV Epidemic

Grant will be used to educate and help prevent the spread of the disease that disproportionately impa... See more »
February 4, 2021Business Wire

Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the c... See more »
February 4, 2021PR Newswire Asia

Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B

Sub-analyses Reinforce Continued Virologic Suppression and Improved Renal and Bone Safety Profile wit... See more »
February 2, 2021Business Wire

Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice

FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Human... See more »

Gilead Videos

Social Media

Gilead Headquarters

333 Lakeside Drive

Foster City, California94404

1-650-574-3000

Driving Directions »

Trending Companies

Gilead Summary

ABOUT

Overview

Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases. Gilead was founded in 1987. Gilead's headquarters is located in Foster City, California, USA 94404. It has raise...

CEO

Gilead's Chairman & CEO, Daniel O’Day, currently has an approval rating of 65%. Gilead's primary competitors are AbbVie, Merck & BMS.

Website

gilead.com

Frequently Asked Questions about Gilead

  1. When was Gilead founded?

    Gilead was founded in 1987
  2. Who is Gilead's CEO?

    Gilead's CEO is Daniel O’Day
  3. How much revenue does Gilead generate?

    Gilead generates $25.6B in revenue
  4. How much funding does Gilead have?

    Gilead has historically raised $7.3B in funding
  5. Where is Gilead's headquarters?

    Gilead's headquarters is in Foster City California, USA
  1. How many employees does Gilead have?

    Gilead has 11,000 employees
  2. What sector does Gilead operate in?

    Gilead is in Pharmaceuticals, Biotechnology
  3. Who are Gilead's competitors?

    Gilead's top competitors are AbbVie, Merck, BMS
  4. Who has Gilead invested in?

    Gilead's has invested in companies such as Vaccitech, Tango Therapeutics, Tizona